Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.40 |
| ▸ | PGR | P06401 | 6/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760512 | 0.89 | AR (0.39) | ARPGRNR3C2NR3C1 | |
| SCHEMBL12306869 | 0.83 | CYP1A2 (0.32) | ARPGR | |
| SCHEMBL12140240 | 0.83 | AR (0.37) | ARPGRNR3C2 | |
| SCHEMBL1364419 | 0.83 | AR (0.37) | ARPGRNR3C1 | |
| SCHEMBL1364311 | 0.83 | AR (0.37) | ARPGRNR3C1 | |
| SCHEMBL12140532 | 0.83 | AR (0.37) | ARPGRNR3C2 | |
| SCHEMBL12138411 | 0.81 | AR (0.56) | ARPGRNR3C2NR3C1 | |
| SCHEMBL19976339 | 0.81 | AR (0.56) | ARPGRNR3C2NR3C1 | |
| SCHEMBL12306106 | 0.81 | AR (0.40) | ARPGRNR3C2NR3C1 | |
| SCHEMBL15712955 | 0.77 | CXCR1 (0.33) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885PGR 28/4885NR3C2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.